7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Cystic Fibrosis of Pancreas

7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with Cystic Fibrosis of Pancreas in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brown, RF; Laposata, M; O'Connor, MG; Seegmiller, A; Thomsen, K	1

Trials

1 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and Cystic Fibrosis of Pancreas

Article	Year
Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study. Prostaglandins, leukotrienes, and essential fatty acids, 2016, Volume: 113 Topics: Adolescent; Arachidonic Acid; Child; Cross-Over Studies; Cystic Fibrosis; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Fatty Acids; Female; Humans; Linoleic Acid; Male; Pilot Projects; Prospective Studies; Prostaglandins; Treatment Outcome	2016

Article

Year

Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study.

Prostaglandins, leukotrienes, and essential fatty acids, 2016, Volume: 113

Topics: Adolescent; Arachidonic Acid; Child; Cross-Over Studies; Cystic Fibrosis; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Fatty Acids; Female; Humans; Linoleic Acid; Male; Pilot Projects; Prospective Studies; Prostaglandins; Treatment Outcome

2016